-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, the official website of NMPA showed that BeiGene's dartuximab beta was approved for marketing for neuroblastoma
Dinutuximab beta (Dinutuximab beta) is a monoclonal antibody that binds to a specific GD2 target that is overexpressed on neuroblastoma cells
On January 13, 2020, EUSA Pharma (hereinafter referred to as EUSA) and BeiGene announced that the two parties have reached exclusive development and commercialization of orphan biologics drugs SYLVANT® (stuximab) and QARZIBA® (dinutuximab beta) in Greater China Agreement
Neuroblastoma is a malignant tumor of the sympathetic nervous system.
At present, in addition to surgery and radiotherapy, the drugs used to treat neuroblastoma include chemotherapeutic drugs and immunotherapy drugs, with limited treatment options
According to the Insight database, only 3 monoclonal antibody products targeting GD2 for the treatment of neuroblastoma have been approved globally.
Among the products under research with the same target, in addition to these three monoclonal antibodies, there are four other projects, all of which are CAR-T products in the early clinical stage
Global R&D Overview: Neuroblastoma therapeutic drugs targeting GD2
From Insight Global New Drug Library (http://db.
Note: The original text has been deleted
